Survodutide
Dual GLP-1 and glucagon receptor agonist (BI 456906) from Boehringer Ingelheim. The 4.8 mg dose gave -14.9% body weight at 46 weeks in phase 2.
Calorize — peptide protocol & nutrition tracker
This substance is still in clinical trials and is not approved for use as a medicine in any country. The figures below come from published trial protocols; they describe what was studied, not what you should take.
Every figure on this page is a dose reported in published sources. It is reference information, not a recommendation and not a protocol to follow. Any decision about injecting is one to make with a doctor.
Medical disclaimerWhat is Survodutide?
Survodutide (BI 456906) is a dual GLP-1 and glucagon receptor agonist. The GLP-1 arm suppresses appetite while the glucagon arm additionally raises energy expenditure, which sets this class apart from pure GLP-1 agents such as semaglutide.
What follows is dosing arithmetic and numeric protocols drawn from published sources and clinical trials. It describes what those sources report; it is not medical advice and not instructions for use. This part of the page is meant for people aged 18 and over.
The confirmation is kept in this browser, and on the account for signed-in users. The peptide description and its regulatory status are available without it.
What follows is dosing arithmetic and numeric protocols drawn from published sources and clinical trials. It describes what those sources report; it is not medical advice and not instructions for use. This part of the page is meant for people aged 18 and over.
The confirmation is kept in this browser, and on the account for signed-in users. The peptide description and its regulatory status are available without it.
Rapid weight loss burns muscle along with fat — that is what sits behind Ozempic face. Enough protein is what separates the two.
Check Protein Norm